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ABSTRACT
Background. Several trials are presently randomizing
clinically node-negative breast cancer patients treated with
breast-conserving therapy (BCT) to sentinel lymph node
biopsy (SLNB) or watchful waiting. We aimed to investigate
the elective radiation dose at the sentinel lymph node (SLN)
site while evaluating two techniques for SLN localization, in
breast cancer patients treated with lumpectomy and three-
dimensional (3D) whole-breast radiotherapy.
Methods. The SLN site of consecutive Tis-2N0 breast
cancer patients undergoing lumpectomy and forward inten-
sity-modulated whole-breast radiotherapy was determined
by the location of the hotspot on preoperative single-photon
emission computed tomography (SPECT)/computed to-
mography (CT) and by a surgical clip placed at the removed
SLN(s) during SLNB. The radiation dose at the SLN site was
subsequently determined on the postoperative radiotherapy
planning CT. An elective radiation dose to the SLN site was
defined as at least 95 % of the breast dose.
Results. Of the 42 included patients, the mean percentage
of the breast dose on the SLN site was 90 % (standard
deviation 26, range 7–132, median 99), with a non-sig-
nificant difference between the two techniques (surgical
clip or SPECT/CT) (p = 0.608). In 32/42 patients (76 %)
the SLN site received an elective radiation dose.
Conclusions. A surgical clip placed at the removed
SLN(s) during SLNB proved to be an adequate method of
determining the radiation dose at the SLN site when
compared with using SPECT/CT. With the use of 3D ra-
diotherapy, the site of the SLN is treated with an elective
radiation dose in the majority of patients who are treated
with BCT.
The treatment of breast cancer with breast-conserving
therapy (BCT) as a less invasive alternative to mastectomy
was introduced in the early 1980s. The addition of whole-
breast radiotherapy to lumpectomy resulted in not only
lower local recurrence rates but also lower regional re-
currence rates.1,2 A meta-analysis showed that in sentinel
lymph node (SLN)-negative patients, whole-breast radio-
therapy after lumpectomy is associated with a lower risk of
axillary recurrence (odds ratio 0.29; p\ 0.001).3 In the
American College of Surgeons Oncology Group (ACO-
SOG) Z0011 trial, SLN-positive patients treated with BCT
were randomized to completion axillary lymph node dis-
section or watchful waiting.4 The regional recurrence rate
was not increased in the watchful-waiting arm, while it is
estimated that 27 % had residual nodal disease that was not
surgically removed.5 It is suggested that these findings
might be partly explained by incidental irradiation of the
lower axilla by whole-breast radiotherapy.6,7 Studies have
shown that up to 73 % of axillary level I and 26 % of level
II receive an elective radiation dose with conventional two-
dimensional (2D) whole-breast radiotherapy.8-10
Presently, several independent trials are randomizing
clinically node-negative breast cancer patients treated with
BCT to SLN biopsy (SLNB) or watchful waiting—the
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Dutch BOOG 2013-08, Italian SOUND, and British SNIPE
trials.11-13 Studies have shown that the SLN site is radiated
in 78–94 % of patients using conventional 2D whole-breast
radiotherapy.14-16 Meanwhile, three-dimensional (3D) ra-
diotherapy techniques mostly replaced 2D radiotherapy.
Both 3D-conformal radiotherapy (3D-CRT) and (forward)
intensity-modulated radiotherapy (IMRT) are considered
3D radiotherapy techniques. In 3D-CRT, the shape of the
radiation field is adapted to the shape of the target volume
but can still lead to high doses in non-target volumes. In
IMRT, the shape of the high-dose volume is as conformal
as possible to the 3D shape of the target volume, and,
furthermore, delivers a more homogeneous dose to the
target volume than 3D-CRT.10 IMRT can thus be consid-
ered as a more advanced and more accurate type of 3D
radiotherapy. It is questionable whether, with a contem-
porary radiation technique, the SLN still receives an
elective radiation dose as more advanced radiotherapy re-
sults in more accurate irradiation of the targeted volume
and less dose to non-target volumes.
Previous studies on the radiation dose at the SLN site used
surgical clips as a marker, representing the postoperative situa-
tion of a minimally dissected axilla. As trials are investigating
the safety of omitting the SLNB, we were interested in the SLN
site in the undissected axilla. For this purpose, preoperative
single-photon emission computed tomography (SPECT)/com-
puted tomography (CT) images seem more appropriate and
were therefore performed in a proportion of patients.
We aimed to investigate whether the radiation dose at
the surgical clip that is placed at the location of the re-
moved SLN(s) during SLNB corresponds to the dose at the
region of increased tracer uptake (the hotspot) on SPECT/
CT, and, furthermore, whether the SLN site receives an
elective radiation dose, in breast cancer patients treated




Consecutive patients diagnosed with unifocal cTis-2N0
breast cancer or carcinoma in situ of the breast between
March 2013 and January 2014, and were about to undergo
BCT and SLNB in our breast center, were included. Pa-
tients receiving completion axillary treatment or with a
history of surgery or radiotherapy of the ipsilateral breast
or axilla were excluded. The acquisition of informed con-
sent was waived by the Medical Ethics Committee (MEC
UM 13-4-019). One group of patients (n = 10) had both
preoperative SPECT/CT images of the axillary region and
a surgical clip placed at the location of the removed SLNs
to evaluate if these methods were equivalent, while a
second group of patients (n = 32) had only the surgical
clip placed at the SLN site.
Sentinel Lymph Node Biopsy
For the SLNB, a total of 80 MBq Technetium-99
nanocolloid (Nanocoll; GE Healthcare, Eindhoven, The
Netherlands) was injected intradermally in the periareolar
region, followed by lymphoscintigraphic images. Addi-
tionally, integrated SPECT/CT images were available in
patients who participated in an ongoing prospective study
concerning non-invasive nodal staging (MEC UM 12-0-36).
All SPECT/CT images were performed using the same po-
sitioning and fixation system as used during the radiotherapy
planning CT and treatment, with the patient in the supine
position, the head in a contoured headrest, and both arms
above the head in the cranial arm holder combined with two
upper-arm supports (PosirestTM-2 system; Cablon Medical
B.V., Leusden, The Netherlands). Two hours after injection,
the SPECT/CT images were obtained (Precedence SPECT/
6-slice CT scanner; Philips, Best, The Netherlands).
The SLN(s) were identified during surgery by using the
lymphoscintigraphic images, blue dye (Bleu Patente V;
Guerbet, Aulnay-sous-Bois, France) and gamma probe.
The surgeon placed a surgical clip(s) at the location of the
removed SLN(s).
Radiotherapy Planning Scans
All patients were routinely scheduled for a radiotherapy
planning CT within 5 weeks after surgery (SOMATOM
Sensation 10; Siemens, Forchheim, Germany). Patients
were positioned as described in the previous section.
Radiation Therapy Details
The prescribed breast dose was 16 9 2.67 Gy in 23
patients; 16 patients received a modified scheme with a low
boost (21 9 2.17 Gy and simultaneous integrated boost
[SIB] of 21 9 2.66 Gy); and three patients received a
modified scheme with a high boost (23 9 2.03 Gy and SIB
of 23 9 2.66 Gy). Delineation of the breast and tumor bed
was performed as described earlier.17,18 In short, for de-
lineation of the breast, a radiopaque wire was used to mark
the palpable breast tissue. The clinical target volume
(CTV) of the breast was defined 5 mm under the skin
surface, in front of the major pectoral muscle and chest
wall, borders largely determined by the radiopaque wire.
Cranially, the CTV breast did not extend above the supe-
rior border of the sternoclavicular joint, and the medial
border of the CTV did not extend beyond the lateral edge
of the sternum. The tumor bed was delineated using all
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preoperative available information, such as mammography,
magnetic resonance imaging (MRI) and physical ex-
amination. For the CTV of the tumor bed, a margin of
1.5 cm minus the minimally free resection margin was
applied around the tumor bed. The CTV of the tumor bed
did not extend into the chestwall, and remained 5 mm
beneath the skin. CTV planning target volume (PTV) ex-
pansion was 5 mm in all directions for both the breast and
the tumor bed, except towards the skin surface where no
CTV–PTV margin was taken.
The forward IMRT technique was used for treatment
planning, as described earlier.18 With this technique we
always start with two open tangential beams, and we op-
timize the dose distribution with additional segments and/
or beams. In our patient population we found that addi-
tional segments (\3 segments) were needed in one-third of
patients, and additional beams (\2 beams) were needed in
two-thirds of patients.
The dose homogeneity constraints for the PTVs were
kept to vary between 95 and 107 % of the prescribed dose.
The lung constraints consisted of a central lung distance
below 3 cm, the mean lung dose had to be \7.5 Gy, the
heart constraints consisted of a maximum heart distance
below 1 cm, the heart volume receiving[10 Gy had to be
\5 %, and the heart volume receiving [5 Gy had to be
\10 %.19 Moderately voluntary breath-holding techniques
to reduce heart dose in left-sided breast cancer were
applied.18
The radiation oncologists and radiation technicians were
blinded for the study aim and procedure at the time of
treatment of all patients.
Data Collection and Statistical Analyses
Data concerning diagnosis and treatment were collected.
The x, y, and z axis coordinates of the center of the SPECT
hotspot were determined on SPECT/CT, after which they
were converted by using the x, y, and z axis coordinates
(0,0,0) of the planning CT scan, followed by visualization of
these coordinates on the planning CT scan. The surgical clip
was also visualized on the planning CT scan. The corre-
sponding radiation dose, expressed as a percentage of the
prescribed breast dose, was determined at the location of the
SPECT hotspot and the surgical clip, at the center of these
points in both techniques. In case of multiple clips due to the
removal of several SLNs, the lowest radiation dose was
obtained. An elective radiation dose to the SLN site was
defined as at least 95 % of the prescribed breast dose.
Descriptive categorical data are presented as proportions
and absolute numbers. Continuous variables are presented
as means with standard deviations (SD). The Bland–Alt-
man and one-sample t-tests were used to analyze the
agreement between the radiation dose delivered to the
surgical clip and the hotspot, with 95 % limits of agree-
ment. Fisher’s exact test was used to analyze if the location
of the tumor in the breast, the size of the breast, or a left-
versus right-sided lesion were predictors for not receiving
an elective radiation dose at the SLN site, and binary lo-
gistic regression for body mass index (BMI), radiation
therapy boost, and a tumor located in the laterocranial
quadrant. Statistical analyses were performed using Sta-
tistical Package for the Social Sciences (SPSS), version
20.0 (IBM Corporation, Armonk, NY, USA). A p value of
\0.05 was considered statistically significant.
RESULTS
Mean age of the ten patients with both SPECT/CT im-
ages and a surgical clip was 63 years (SD 11, range 50–79,
median 63) and mean tumor size was 12 mm (SD 8, range
4–26, median 11). Radiation dose on the SPECT hotspot
and surgical clip of the ten patients are presented in
Table 1. Mean radiation dose on the SPECT hotspot was
38.92 Gy (SD 8, range 20–45) and on the surgical clip
38.62 Gy (SD 9, range 16–45). The mean percentage of the
breast dose at the SPECT hotspot and the surgical clip was
89 % (SD 17, range 48–105) and 88 % (SD 20, range
37–104), respectively. The mean difference between the
two methods was -0.0076 (95 % limits of agreement
±0.0899) (p = 0.608).
Because the percentages of the elective radiation dose at
the surgical clip and the SPECT hotspot were in line,
further analyses were performed on all 42 patients. Patient
demographics and tumor characteristics of the 42 patients
are shown in Table 2. The percentages of the breast dose
on the surgical clip of all patients are shown in Fig. 1. The
mean percentage of the breast dose on the surgical clip was
90 % (SD 26, range 7–132, median 99 %). The SLN site
received at least an elective radiation dose in 32 patients
(76 %). An example of a patient with an elective radiation
dose on the surgical clip is shown in Fig. 2. In 35 of 42
patients (83 %), at least 90 % of the breast dose was de-
livered, at least 80 % in 36 patients (86 %), and at least
50 % in 37 patients (88 %) (Table 3). The location of the
tumor in the breast, the size of the breast, a left- versus
right-sided lesion or BMI, and the combination of radiation
therapy boost with a tumor located in the laterocranial
quadrant did not influence the elective radiation dose at the
SLN site.
DISCUSSION
This study aimed to investigate the incidental radiation
dose to the SLN site in breast cancer patients treated with
lumpectomy followed by whole-breast radiotherapy using
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forward IMRT, to illustrate incidental treatment of the SLN
in trials investigating the safety of omitting the SLNB. A
surgical clip placed at the location of the removed SLN(s)
during SLNB proved to be an adequate method to deter-
mine the radiation dose at the SLN site when compared
with using SPECT/CT images. An elective radiation dose,
i.e. [95 % of the total breast dose, was delivered to the
SLN site in 76 % of patients.
The hotspot on SPECT/CT represents the preoperative
localization of the SLN site in an undissected axilla. This
method therefore seems appropriate to simulate the situa-
tion where the SLNB is omitted. The SLN site can be
visualized without postoperative effects, such as hematoma
or seroma, which can influence the configuration of the
lymph nodes within the axilla. However, there are some
limitations in the use of SPECT/CT for accurate localiza-
tion of the SLN site. At first, the attenuation of the SPECT
and CT images can be technically challenging, for example
due to respiratory motion artifacts.20 Second, the compo-
sition of the axilla could change by (oncoplastic) surgery of
the breast. In that case, the surgical clip method might be
more appropriate for adequate SLN localization. However,
results of our study showed that the percentage of the
prescribed breast dose at the hotspot was in line with the
surgical clip in ten patients.
3D-CRT and forward IMRT have now mostly replaced
conventional 2D radiotherapy for breast irradiation. The
benefit of 3D radiotherapy includes more accurate irra-
diation of the targeted volume and reduced toxicity to
surrounding tissue. In whole-breast radiotherapy this might
result in a decreased incidental radiation dose to, among
others, the axilla, with the hypothetical advantage of a
decreased risk of lymphedema and fibrosis.21 On the con-
trary, a reduced dose to the axilla could negatively affect
the incidental benefit of a decreased regional recurrence
rate in patients treated with BCT.3 As conventional 2D
radiotherapy instead of 3D radiotherapy techniques were
routinely used in the ACOSOG Z0011 trial, it is suggested
that radiotherapy should be extended to include axillary
level I–II to maintain excellent regional control when ap-
plying Z0011 results in today’s practice.22 Indeed, Kataria
et al. showed a relatively small, although significant, dif-
ference in the axillary radiation dose when comparing
conventional 2D radiotherapy with 3D-CRT or IMRT. The
mean percentage of axillary level I that received at least
90 % of the total breast dose was 73 % for conventional
2D radiotherapy, 57 % (p = 0.029) for 3D-CRT, and 49 %
(p = 0.029) for IMRT; for level II, the mean percentage
was 25, 41 % (p = 0.028), and 35 % (p = 0.068), re-
spectively.10 The current study was the first to investigate
the radiation dose to the SLN site with 3D breast radio-
therapy, and, more specifically, with IMRT. The elective
radiation dose to the SLN in 76 % of patients in our study
is in line with the percentage of 78 % reported by Rabi-
novitch et al., and lower than the 85 % reported by
Schlembach et al. and the 94 % reported by Chung et al.,
which were all studies using conventional 2D breast ra-
diotherapy.14-16 As described earlier, IMRT can be
considered as a more advanced and more accurate type of
3D radiotherapy when compared with 3D-CRT. Together
with results of the study of Kataria et al.,10 it is likely that a
higher percentage of patients will have an elective radiation
dose to the SLN when evaluating 3D-CRT. Therefore, we
find that even with contemporarary 3D techniques, the SLN
still receives an adequate dose in the majority of patients.
The location of the tumor in the breast, the size of the
breast, a left- versus right-sided lesion, a radiation therapy
boost, and BMI are sometimes referred to as factors
TABLE 1 Radiation dose and percentage of prescribed whole-breast dose on SPECT hotspot and surgical clip in ten patients
Radiation scheme
to the whole breast
Total prescribed
dose to breast (Gy)





Dose (Gy) Percentage of total
breast dose (%)
1 16 9 2.67 42.72 35.50 83.10 37.20 87.08
2 16 9 2.67 42.72 44.60 104.40 44.58 104.35
3 16 9 2.67 42.72 32.40 75.84 30.88 72.28
4 16 9 2.67 42.72 41.50 97.14 41.10 96.21
5 16 9 2.67 42.72 20.40 47.75 15.90 37.22
6 16 9 2.67 42.72 41.50 97.14 41.65 97.50
7 21 9 2.17 45.57 42.00 92.17 43.40 95.24
8 21 9 2.17 45.57 42.80 93.92 43.46 95.37
9 21 9 2.17 45.57 43.50 95.46 45.10 98.97
10 16 9 2.67 42.72 44.97 105.27 42.90 100.42
Radiation scheme: the number of fx 9 dose per fx in Gy to the whole breast
SPECT single-photon emission computed tomography
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influencing the amount of radiation to the axilla. Our study
failed to demonstrate a relation between these factors and
not receiving an elective radiation dose at the SLN site.
The location of the SLN posteriorly or high in the axilla is
more likely to explain why these patients have a lower
radiation dose at the SLN, but we did not analyze this in
our cohort. The study by Uren et al. showed that the ax-
illary SLN is located anteriorly or centrally in axillary level
I in 83 % of patients, and the remaining proportion more
posteriorly in level I or in level II–III.23 Furthermore, the
site of the tracer injection for SLNB influences the drainage
pattern and thus the location where the SLN appears. In
periareolar injections, as performed in our cohort, a higher
proportion of patients have drainage to the anterior region
of axillary level I (57 %) compared with peritumoral in-
jections (46 %) (p = 0.042).23
In the current study, an elective radiation dose was de-
livered to the SLN site in 76 % of patients, and in 86 % of
patients the SLN site received at least 85 % of the elective
radiation dose (Table 3). The optimal dose for curative
radiation of metastatic disease in lymph nodes is ques-
tionable and might be less than 95 % of the prescribed
breast dose. Lower doses could result in a decreased effect
but might still be effective in subclinical disease. Evidence
exists for sufficient control of several cancer types with low
radiation doses ranging from 10 to 30 Gy.24,25 Withers and
Suwinski proposed that the dose response curve for mi-
croscopic disease is different from the curve for
macroscopic disease, and that a lower radiation dose in
these patients is probably equally effective.26 However,
because the amount of residual subclinical disease differs
among patients, it is not possible to predefine the elective
radiation dose for the individual patient.
For the comparison of SPECT/CT and the surgical clip
as methods for determining the elective radiation dose at
the SLN site, the data of ten patients were used in our
study. It is not expected that results would be affected if
more patients had been analyzed because the percentage of
patients receiving an elective radiation dose at the SLN site
is comparable to what is shown in the available lit-
erature.14-16 Final analyses in this study were performed
on existing radiation therapy plans of 42 patients, and we
did not assess delineation and inter-observer variation, but
the radiation oncologists and radiation technicians were
blinded for the study aim and procedure at the time of
treatment of all patients. Despite the growing popularity of
TABLE 2 Patient demographics and tumor characteristics of all
patients
Characteristic Value
Number of patients 42
Age, years
Mean (SD) 66 (9)
Range 48–81
Tumor size, mm
Mean (SD) 17 (10)
Range 4–50
Number of sentinel lymph nodes removed
Mean (SD) 1.45 (0.8)
Range 1–4
Number of non-sentinel lymph nodes removed








pN0(i ?) 1 (2)
pN1mi 4 (10)
pN1 1 (2)
Tumor type [N (%)]
Ductal carcinoma in situ 3 (7)
Invasive ductal carcinoma, NOS 32 (76)
Invasive lobular carcinoma, NOS 3 (7)
Other 4 (10)
Affected side [N (%)]
Left 21 (50)
Right 21 (50)









Location of tumor in breast [N (%)]
Laterocranial quadrant 23 (55)
Laterocaudal quadrant 7 (17)
Mediocranial quadrant 5 (12)
Mediocaudal quadrant 7 (17)






[ 35 2 (5)
SD standard deviation, NOS not otherwise specified, BMI body mass
index
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partial breast radiotherapy, we did not include patients
receiving this treatment in our analysis because in The
Netherlands it is almost only applied within clinical trials
and because the mentioned trials investigating the safety of
omitting the SLNB only include clinically node-negative
breast cancer patients when they are treated with
lumpectomy and whole-breast radiotherapy.11-13 It can be
expected that for partial breast radiotherapy, the amount of
radiation to the SLN is highly influenced by the location of
the tumor in the breast, while this was not the case in our
cohort.
CONCLUSIONS
A surgical clip placed at the location of the removed
SLN during SLNB proved to be an adequate method of
determining the radiation dose at the SLN site when
compared with using SPECT/CT images. With the use of
3D radiotherapy, the site of the SLN is treated with an
elective radiation dose in the majority of patients who are
treated with BCT. Whole-breast radiotherapy after
lumpectomy in patients in whom the SLNB is omitted
might therefore help to prevent an increase of the regional
recurrence rate. The safety of omitting the SLNB should be
confirmed by the initiated randomized controlled trials.
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FIG. 2 Radiotherapy planning CT of a study patient after lumpectomy
and SLNB with an elective radiation dose at the surgical clip. The breast
tumor of this patient was located in the mediocaudal quadrant of the
breast; the tumor bed is not visible on this CT image. The yellow line
contouring the breast represents the 95 % isodose, i.e. all spots on this line
received at least 95 % of the prescribed dose; the orange line represents
the 90 % isodose; thedarkblue line represents the 50 % isodose; the light
blue line represents the clinical target volume of the breast; and the red
line represents the planning target volume of the breast. The surgical clip
at the SLN site is contoured by a green line. CT computed tomography,

















































FIG. 1 Percentage of prescribed
whole-breast dose on the surgical clip at
the SLN site in 42 patients. The yellow
line represents 95 % of the prescribed
whole-breast dose at the surgical
clip. SLN sentinel lymph node
TABLE 3 Number of patients receiving at least 95, 90, 85, 80 or
50 % of the prescribed whole-breast dose on surgical clip
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